Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2843-2852

  Cheng, Jian ^a   Cheng, Lin ^a   Chen, Baoan ^a,b   Xia, Guohua ^a   Gao, Chong ^a   Song, Huihui ^a   Bao, Wen ^a   Guo, Qinglong ^c   Zhang, Haiwei ^c   Wang, Xuemei ^b  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Daunorubicin; Fe3O4; Magnetic nanoparticles; Multidrug resistance; P glycoprotein; Wogonin

Indexed keywords

COPOLYMER; DAUNORUBICIN; MAGNETIC NANOPARTICLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; WOGONIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE 1 GENE; MYELOID LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DAUNORUBICIN; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLAVANONES; FLOW CYTOMETRY; HUMANS; K562 CELLS; MAGNETITE NANOPARTICLES; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84870310322     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32065     Document Type: Article

References (27)

1. Parasrampuria R, Mehvar R. Divergent effects of nitric oxide donors on the biliary efflux transporters in isolated perfused rat livers: nitric oxideindependent inhibition of ABC transporters by sodium nitroprusside. Drug Metab Lett. 2011;5(1):64-72.
2. Lee CA, Cook JA, Reyner EL, Smith DA. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol. 2010;6(5):603-619.
3. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther. 2007;113(2): 429-441.
4. Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A. Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in the rat. Xenobiotica. 2010;40(1):55-61.
5. Luurtsema G, Schuit RC, Klok RP, et al. Evaluation of taniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009;36(6):643-649.
6. Friedenberg WR, Tallman MS, Brodsky I, et al. Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group. Leuk Res. 2004;28(8):813-819.
7. Abraham J, Edgerly M, Wilson R, et al. A Phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res. 2009;15(10):3574-3582.
8. Ishii K, Tanaka S, Kagami K, et al. Effects of naturally occurring polymethyoxyflavonoids on cell growth, p-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells. Cancer Invest. 2010;28(3):220-229.
9. Enomoto R, Suzuki C, Koshiba C, et al. Wogonin prevents immunosuppressive action but not anti-inflammatory effect induced by glucocorticoid. Ann N Y Acad Sci. 2007;1095:412-417.
10. 4and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int J Nanomedicine. 2009;4:209-216.
11. Cheng J, Wang J, Chen B, et al. A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomedicine. 2011; 6:2123-2131.
12. 4nanoparticles with 2-methoxyestradiol on the cell-cycle progression and apoptosis of myelodysplastic syndrome cells. Int J Nanomedicine. 2011;6: 1921-1927.
13. Wang L, Zhang H, Chen B, et al. Effect of magnetic nanoparticles on apoptosis and cell cycle induced by wogonin in Raji cells. Int J Nanomedicine. 2012;7:789-798.
14. Collnot EM, Ali H, Lehr CM. Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. January 25, 2012. [Epub ahead of print.]
15. Philchenkov AA, Zavelevich MP, Mikhailenko VM, Kuyava LM. Apoptosis and content of mobile lipid domains in human leukemia K-562 cells induced to differentiate by quercetin or dimethyl sulfoxide. Ukr Biokhim Zh. 2010;82(2):104-110. Ukrainian.
16. 4nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells. Int J Nanomedicine. 2009;4:107-114.
17. Battisti RF, Zhong Y, Fang L, et al. Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance. Mol Pharm. 2007;4(1):140-153.
18. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(1):89-99.
19. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
20. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
21. Hueber A, Esser JM, Kociok N, et al. Mitomycin C induces multidrug resistance in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2008;246(2):297-304.
22. Gupta AK, Wells S. Surface-modified superparamagnetic nanoparticles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans Nanobioscience. 2004;3(1):66-73.
23. Cole AJ, Yang VC, David AE. Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol. 2011;29(7):323-332.
24. Ho PC, Ghose K, Saville D, Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol. 2000;56(9-10):693-698.
25. Peng J, Qi Q, You Q, et al. Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. J Ethnopharmacol. 2009;124(2):257-262.
26. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release. 2006;116(3):275-284.
27. Xiong XB, Ma Z, Lai R, Lavasanifar A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials. 2010;31:757-768.